- Home
- BIIB vs BEKE Comparison
BIIB vs BEKE Comparison
Compare BIIB & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BEKE
- Stock Information
- Founded
- BIIB 1978
- BEKE 2001
- Country
- BIIB United States
- BEKE China
- Employees
- BIIB N/A
- BEKE N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BEKE Real Estate
- Sector
- BIIB Health Care
- BEKE Finance
- Exchange
- BIIB Nasdaq
- BEKE Nasdaq
- Market Cap
- BIIB 25.1B
- BEKE 24.7B
- IPO Year
- BIIB 1991
- BEKE 2020
- Fundamental
- Price
- BIIB $149.02
- BEKE $18.48
- Analyst Decision
- BIIB Buy
- BEKE Strong Buy
- Analyst Count
- BIIB 26
- BEKE 4
- Target Price
- BIIB $248.00
- BEKE $25.97
- AVG Volume (30 Days)
- BIIB 1.6M
- BEKE 6.6M
- Earning Date
- BIIB 02-11-2025
- BEKE 11-21-2024
- Dividend Yield
- BIIB N/A
- BEKE 1.90%
- EPS Growth
- BIIB 10.05
- BEKE N/A
- EPS
- BIIB 11.06
- BEKE 0.50
- Revenue
- BIIB $9,607,500,000.00
- BEKE $11,766,571,657.00
- Revenue This Year
- BIIB N/A
- BEKE $13.86
- Revenue Next Year
- BIIB N/A
- BEKE $11.10
- P/E Ratio
- BIIB $13.47
- BEKE $36.70
- Revenue Growth
- BIIB N/A
- BEKE 11.06
- 52 Week Low
- BIIB $145.07
- BEKE $12.44
- 52 Week High
- BIIB $268.30
- BEKE $26.05
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- BEKE 41.68
- Support Level
- BIIB $145.07
- BEKE $17.89
- Resistance Level
- BIIB $149.92
- BEKE $19.39
- Average True Range (ATR)
- BIIB 3.81
- BEKE 0.71
- MACD
- BIIB 0.05
- BEKE -0.08
- Stochastic Oscillator
- BIIB 22.51
- BEKE 12.80
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BEKE KE Holdings Inc (each representing three)
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2023, Beike's cofounders collectively control the company, while Tencent and its affiliates share 8% of voting power.